Following the results of the UK’s referendum on 23 June, the life sciences industry needs to prepare for the impact of a change in the relationship between the UK and EU. The impact will differ from company to company, but it is possible to shed light on the extent, the timing and who in the industry will be affected, by considering the different activities in the industry value chain and the role of European rules and regulation. To read more, click the link below.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...